<DOC>
	<DOCNO>NCT01832051</DOCNO>
	<brief_summary>Information presence human epidermal growth factor receptor 2 ( HER2 ) tumor lesion breast cancer patient essential diagnostic therapeutic management metastatic breast cancer . In daily practice however , obtain metastasis biopsy difficult impracticable . Therefore , clinician face persistent clinical dilemma breast cancer patient , lead suboptimal therapy decision due lack HER2 receptor information . Circulating tumor cell ( CTCs ) , may provide additional information , far able replace biopsy . To solve problem , non-invasive whole body visualization quantification HER2 expression mean HER2-PET may valuable tool . In prospective multicenter image study , eligible patient receive one HER2-PET CTC analysis addition standard work metastatic disease . Subsequent administration anti-HER2 therapy evaluate . Referring physician fill three questionnaire , one HER2-PET two HER2-PET .</brief_summary>
	<brief_title>Clinical Value 89Zr-trastuzumab PET</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>1 . Patients history histological and/or cytological proven HER2positive primary breast cancer . In Netherlands HER2positivity define : HER2 immunohistochemical score 3+ , HER2 immunohistochemical score 2+ positive FISH HER2/cerbB2 amplification . In Belgium HER2positivity define positive FISH HER2/cerbB2 amplification . 2 . Patients suspect metastatic disease local recurrence HER2positive breast cancer clinical dilemma : standard work image fail solve clinical dilemma ( diagnostic/therapeutic ) , leave issue regard HER2 status lesion biopsy desirable ( easily ) perform due technical patient factor otherwise . 3 . Standard workup imaging define CT chest abdomen , bone scintigraphy , well FDGPET . 4 . Age &gt; 18 year age . 5. WHO performance status 02 . 6 . Signed write informed consent . 7 . Able comply protocol . 1 . Pregnant lactating woman . 2 . Prior allergic reaction immunoglobulin immunoglobulin allergy . 3 . Inability comply study procedure</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>HER2-PET</keyword>
	<keyword>89Zr-trastuzumab</keyword>
	<keyword>metastatic breast cancer</keyword>
	<keyword>clinical dilemma</keyword>
</DOC>